

Hypobaric & Hyperbaric Conditions

Arthur Jones, EdD, RRT

Learning Objectives:

- △ Explain the etiologies, pathophysiology, manifestations, complications and management of hypobaric and hyperbaric conditions.
- △ Explain the rationale, indications, complications, procedures and equipment associated with hyperbaric oxygen therapy.

Gas Laws

Pertinent gas laws

- △ Boyle's law - relationship between volume and pressure
- △ Henry's law - solubility of gases in liquids
- △ Dalton's law - law of partial pressures

Boyle's law

- △ For a given mass of gas at a constant temperature, the volume times the pressure equals a constant.

◆ $PV = \text{Constant}$

◆ $P_1V_1 = P_2V_2 \implies V_2 = P_1V_1/P_2$

Boyle's law

- △ The volume is inversely proportional to the pressure \implies
 - ◆ increasing pressure \implies decreases volume
 - ◆ decreasing pressure \implies increases volume

FYI - Click for demonstration of Boyle's law
<http://www.grc.nasa.gov/WWW/K-12/airplane/boyle.html>

Boyle's law

- ^ Pressure is measured in atmospheres (Atm) or absolute (ATA)
- ^ 1 ATA = 760 mm Hg = 14.7 psi
- ^ A balloon contains 1.0 L at 1.0 ATA
 - ◆ at 0.5 ATA the V changes to 2.0 L
 - ◆ at 2.0 ATA, the V changes to 0.5 L

Depths, altitude & ambient pressure

- ^ Each 33 ft underwater = 1.0 atm ==>
- @ 33 ft. = 2 ATA (absolute) = 1520 mm Hg
- ^ 19,000 ft. = 0.5 ATA = 380 mm Hg
- ^ Mt. Everest summit = 0.33 ATA = 250 mm Hg
- ^ 100,000 ft. approaches zero ATA (FO2 remains 0.21)

FYI - Click for chart with altitudes and pressure
http://www.engineeringtoolbox.com/air-altitude-pressure-d_462.html

Boyle's law

- ^ So????
- ◆ 6 L lung volume compressed to 3 L at 33 ft. depth
- ◆ this would reverse on rapid ascent ==> diver holds breath during ascent and lungs burst from volutrauma
- ◆ gas bubble increase in volume ==> 'bends'

Boyle's law

- ^ Question - the limit to the length of a snorkel for underwater breathing is about 40 cm (16 in.) What is the basis for this limit?

Boyle's law

- ^ Question - the limit to the length of a snorkel for underwater breathing is about 40 cm. What is the basis for this limit?
- ^ Answer - the pressure surrounding the chest at greater depth makes the work of breathing unsustainable.
 - ◆ e.g. - at 1.0 m, the pressure is about 100 cm H2O
 - ◆ with SCUBA gear, the pressure equalizes

Henry's law

- ^ The amount of any given gas that will dissolve in a liquid at a given temperature is a function of the partial pressure of the gas that is in contact with the liquid and the solubility coefficient of the gas in the particular liquid.

Henry's law

^ Examples:

- ◆ $\text{PaO}_2 \times .003 = \text{dissolved O}_2 \implies$
- ◆ $100 \text{ mm Hg} \times .003 = 0.3 \text{ mL/dL}$
- ◆ $2183 \text{ mm Hg} \times .003 = 6.5 \text{ mL/dL}$

FYI - Click for more information on Henry's law
<http://www.800mainstreet.com/9/0009-006-henry.html>

Henry's law

^ So what?

- ◆ hyperbaric oxygen increases dissolved O₂ available to tissues that are not perfused.
- ◆ nitrogen dissolved under hyperbaric conditions produces bubbles during decompression.

Dalton's law

^ The total pressure in a gas mixture equals the sum of the partial pressures of the gases.

^ Alveolar air equation (clinical) -
 $\text{PAO}_2 = \text{FO}_2(\text{Pb} - 47) - (\text{PACO}_2 \times 1.25)$

FYI - Click for Dalton's law
<http://www.chm.davidson.edu/vce/GasLaws/DaltonsLaw.html>

Alveolar air equation

^ At 1.0 ATA a person has a normal $\text{PAO}_2 = 100 \text{ mm Hg}$ ($\text{FIO}_2 = .21$)

◆ @ 6900 ft. $\text{Pb} = 580 \implies$
 $\text{PAO}_2 = .21(580 - 47) - (40 \times 1.25) =$
 62 mm Hg

◆ @ 2 ATA. $\text{Pb} = 1520 \implies$
 $\text{PAO}_2 = .21(1520 - 47) - (40 \times 1.25) =$
 456 mm Hg

**High Altitude Physiology
& Acclimatization**

High altitude (HA)

^ High altitude: 1500 to 3500 m (4921-11,483 ft) - high-altitude illness common with abrupt ascent to above 2500 m (8202 ft)

^ Very high altitude: 3500 to 5500 m (11,483-18,045 ft) - most common range for severe high-altitude illness

Note: ft. = meters x 3.28

High altitude (HA)

- ▲ High altitude: 1500 to 3500 m (4921-11,483 ft) - high-altitude illness common with abrupt ascent to above 2500 m (8202 ft)
- ▲ Very high altitude: 3500 to 5500 m (11,483-18,045 ft) - most common range for severe high-altitude illness
- ▲ Extreme altitude: 5500 to 8850 m (18,045-29,035 ft) - progressive deterioration of physiologic function eventually overcomes acclimatization

High altitude (HA)

- ▲ Highest permanent habitation - La Rinoconada, Peru (5100 m)
- ▲ Lhasa, Tibet (3650 m)

**Living at high altitude (HA)**

- ▲ Acclimatization - changes within an individual to live at HA
- ▲ Adaptation - genetic changes in populations to live at HA (generations living at HA)
 - ◆ indigenous Andeans - minimal, if any adaptation
 - ◆ indigenous Tibetans - adaptations; e.g, normal pulmonary artery pressure

High altitude alterations

- ▲ Stimulus for all mechanisms is hypobaric hypoxia
- ▲ Hypoxic ventilatory response (HPV)
 - ◆ peripheral chemoreceptors adjust ventilation for increased PaO₂.
 - ◆ occurs immediately
 - ◆ capability to withstand extreme hypocapnea is one form of acclimatization

High altitude alterations

- ▲ HbO₂ dissociation curve
 - ◆ hypocapnea shifts curve to left
 - ▶ increases alveolar O₂ uptake
 - ▶ inhibits release of O₂ to tissues
 - ◆ increased production of 2,3 DPG shifts the curve rightward, increasing release of O₂ to tissues - partial compensation for hypocapnea

Pearl: One Everest climber developed a P₅₀ = 19 mm Hg (normal = 27 mm Hg)

High altitude alterations

- ▲ Acid-base balance
 - ◆ hypocapnea ==> respiratory alkalemia
 - ◆ chronic hypocapnea causes kidneys to excrete HCO₃⁻ to balance pH - e.g.: pH = 7.45; PCO₂ = 28; HCO₃ = 19; base change = - 5 mEq/L
 - ◆ return to normal PCO₂ causes acidemia and hyperventilation until HCO₃⁻ is retained

High altitude alterations**^ Cardiovascular changes**

- ◆ heart rate and cardiac output
 - ▶ initial increase in heart rate and cardiac output
 - ▶ resting heart rate returns toward normal over time
- ◆ pulmonary vasoconstriction ==> pulmonary hypertension

High altitude alterations**^ Cerebral circulation**

- ◆ hypobaric hypoxia increases cerebral blood flow
- ◆ hypocapnea decreases cerebral blood flow
- ◆ cognitive impairment begins at 2500 m

FYI - click to see video of high-altitude training for pilots
<http://www.youtube.com/watch?v=CptmVSXnEfc>

High altitude alterations**^ Hematology - hypoxia stimulates erythropoietin release, which increases RBC production**

- ◆ begins after 2 H at altitude
- ◆ increases oxygen content

Pearl: Theoretically, genetic variations that permit survival at high altitude also improve outcomes in critical illness.

High altitude alterations**^ Peripheral tissues - increased myoglobin**

- ◆ increases diffusion of O₂ to muscles
- ◆ additional reservoir for oxygen

FYI - click to download article on high-altitude physiology
<http://www.ericjlee.com/Mountains/The%20Physiology%20of%20High%20Altitude.pdf>

High Altitude Illness

Conditions

- ^ Acute mountain sickness (AMS)
- ^ High altitude cerebral edema (HACE)
- ^ High altitude pulmonary edema (HAPE)
- ^ Chronic mountain sickness (CMS)

FYI - click to download article on high-altitude illness
<http://www.nepalinternationalclinic.com/downloads/altitude%20sickness%28seminar%29.pdf>

AMS/HACE

- ▲ Acute mountain sickness (AMS) and high altitude cerebral edema (HACE) - same pathophysiology, different levels of severity
- ▲ Etiology - abrupt ascent to altitude >2500 m (8200 ft.)
- ▲ FYI - Vail, Colorado - 2484 m (8150 ft.)

AMS/HACE

- ▲ Risk factors:
 - ◆ rate of ascent
 - ◆ altitude for sleep
 - ◆ individual susceptibility
 - ◆ preexisting cardiopulmonary disease
 - ◆ physical exertion
 - ◆ obesity

AMS/HACE

- ▲ No gender differences in susceptibility
- ▲ Neither youth nor physical fitness confer protection

AMS/HACE

- ▲ Pathophysiology - unclear; but, elements include:
 - ◆ regional cerebral edema
 - ◆ increased intracranial pressure
 - ◆ cerebral vasoreactivity
 - ◆ cerebral vascular leakage

AMS/HACE

- ▲ Symptoms (AMS) - occur 6 - 36 H after ascent
 - ◆ headache
 - ◆ dizziness
 - ◆ disturbed sleep
 - ◆ anorexia, nausea, vomiting
 - ◆ fatigue
 - ◆ shortness of breath
 - ◆ malaise

FYI - click to see Lake Louise altitude illness scoring
<http://www.high-altitude-medicine.com/AMS-LakeLouise.html>

AMS/HACE

- ▲ Symptoms (HACE)
 - ◆ change in mental status; e.g., confusion
 - ◆ photophobia
 - ◆ hallucinations
- ▲ Signs (HACE)
 - ◆ ataxia (discoordination)
 - ◆ coma
 - ◆ can cause death from brain herniation

AMS/HACE & pediatrics

- ▲ Pediatric assessment
 - ◆ infant fussiness
 - ◆ appetite, vomiting
 - ◆ playful activity
 - ◆ afternoon nap

FYI - click for article on pediatric assessment for AMS/HACE
<http://archpedi.ama-assn.org/cgi/reprint/152/7/683.pdf>

Cardiopulmonary conditions & HA

- ▲ COPD
 - ◆ altitude worsens hypoxemia
 - ◆ altitude does NOT adversely affect lung mechanics
 - ◆ baseline PaO₂ = 73 mm Hg required for 2300 m (commercial airline cabins)
 - ◆ patients with FEV₁ < 1.5 L may require supplemental O₂

Cardiopulmonary conditions & HA

- ▲ Asthma
 - ◆ decreased house mite load
 - ◆ air quality can be worse; e.g., diesel exhaust and yak dung fire smoke
 - ◆ hypoxemia can cause bronchospasm
 - ◆ severe asthmatics ascend with caution

FYI - click to download article on high altitude and preexisting lung disease
<http://erj.ersjournals.com/cgi/reprint/29/4/770>

Cardiopulmonary conditions & HA

- ▲ Pulmonary hypertension worsens
- ▲ Patent foramen ovale (PFO)
 - ◆ predisposes to high-altitude pulmonary edema
 - ◆ worsens hypoxemia, due to right-to-left shunt

Cardiopulmonary conditions & HA

- ▲ Obesity hypoventilation - advise against high-altitude travel
- ▲ Obstructive sleep apnea - take CPAP
- ▲ Persons with migraine headaches may require slower ascent

AMS/HACE

- ▲ Prevention
 - ◆ gradual ascent (>2500 m or 8000 ft.)
 - ▶ ≤ 300 m/day
 - ▶ rest day Q 2 - 3 D
 - ▶ no further ascent for symptomatic persons

AMS/HACE**^ Prevention**

- ◆ acetazolamide (Diamox) - carbonic anhydrase inhibitor
 - ▶ ventilatory stimulant
 - ▶ prevents sleep apnea
 - ▶ mimics/hastens acclimatization
 - ▶ makes carbonated beverages taste bad!! (including beer)

AMS/HACE**^ Prevention**

- ◆ acetazolamide (Diamox) - carbonic anhydrase inhibitor
 - ▶ ventilatory stimulant
 - ▶ prevents sleep apnea
 - ▶ mimics/hastens acclimatization
 - ▶ makes carbonated beverages taste bad!!
- ◆ dexamethasone (Decadron) - believed to minimize vascular leakage
- ◆ ginkgo - is NOT effective

AMS/HACE**^ Treatment**

- ◆ descent
 - ▶ > 500 m (1600 ft.)
 - ▶ problematic for back-country trekkers
- ◆ acetazolamide (Diamox)
- ◆ dexamethasone (Decadron)
- ◆ theophylline (under study)

High altitude pulmonary edema (HAPE)**^ Occurrence**

- ◆ ≥ 3000 m
- ◆ 2 - 4 days after ascent
- ◆ may be preceded or accompanied by AMS

HAPE**^ Pathophysiology**

- ◆ hypoxia - accentuated pulmonary vascular response ==> worsened pulmonary hypertension
- ◆ heterogeneous stress failure of pulmonary microvascular endothelium, causing fluid leak into alveoli

HAPE**^ Manifestations - progressive**

- ◆ initial nonproductive cough
- ◆ progressive dyspnea
- ◆ tachypnea
- ◆ tachycardia

HAPE

- ▲ Manifestations - progressive
 - ◆ production of pink, frothy sputum
 - ◆ crackles
 - ◆ severe hypoxemia
 - ◆ patchy infiltrates on chest x-ray
 - ◆ lethargy
 - ◆ coma
 - ◆ death

Click to see radiograph of HAPE

http://img.medscape.com/pi/emed/ckb/pediatrics_general/1331341-1331361-1006029-1006094.jpg

HAPE

- ▲ Susceptibility increased by:
 - ◆ male gender
 - ◆ history of HAPE
 - ◆ patent foramen ovale
 - ◆ pulmonary vascular disease

HAPE

- ▲ Prevention and treatment
 - ◆ precautions, as for AMS/HACE; e.g., graded ascent
 - ◆ pulse oximetry
 - ▶ very high altitudes
 - ▶ susceptible individuals
 - ◆ immediate descent

HAPE

- ▲ Prevention and treatment
 - ◆ precautions, as for AMS/HACE
 - ◆ pulse oximetry
 - ◆ Diamox - reverses pulmonary hypertension
 - ◆ Ca++ channel blocker; e.g., nifedipine (Procardia) - reverses pulmonary hypertension
 - ◆ phosphodiesterase inhibitor; e.g., tadalafil (Cialis) - reverses pulmonary hypertension

HAPE

- ▲ Prevention and treatment
 - ◆ Decadron - stabilizes capillary endothelium
 - ◆ inhaled beta agonists; e.g., salmeterol - high doses increase clearance of alveolar fluid
 - ◆ oxygen
 - ◆ CPAP
 - ◆ hyperbaric oxygen (portable chamber)

Chronic mountain sickness (CMS)

- ▲ AKA - Monge's disease
- ▲ Occurs in high altitude natives or long-term residents (>2500 m)
- ▲ Higher altitude ==>
 - ◆ greater prevalence
 - ◆ greater severity

Chronic mountain sickness (CMS)**^ Categories:**

- ◆ primary CMS - acclimatized individuals who develop idiopathic CMS
- ◆ secondary CMS - individuals with conditions; e.g., obesity, neuromuscular disorders, chronic lung disease

Chronic mountain sickness (CMS)**^ Pathophysiologic components**

- ◆ excessive erythrocytosis (Hct >58%)
- ◆ relative hypoventilation
- ◆ exaggerated hypoxemia
- ◆ pulmonary hypertension, leading to cor pulmonale

Chronic mountain sickness (CMS)**^ Symptoms**

- ◆ dyspnea
- ◆ reduced exercise tolerance
- ◆ headache
- ◆ anorexia
- ◆ burning palms, plantar surfaces
- ◆ muscle & joint pain
- ◆ inability to concentrate
- ◆ memory loss

Chronic mountain sickness (CMS)**^ Signs**

- ◆ excessive erythrocytosis
 - ▶ Hb females >19 g/dL
 - ▶ Hb males >21 g/dL
- ◆ severe hypoxemia, cyanosis
- ◆ pulmonary hypertension, which may result in cor pulmonale

Chronic mountain sickness (CMS)**^ Management**

- ◆ descent - permanent
- ◆ supplemental oxygen
- ◆ acetazolamide (Diamox)
- ◆ phlebotomy (by Vampires?)

Chronic mountain sickness (CMS)**^ Management**

- ◆ antihypertensives (studies needed):
 - ▶ Ca⁺⁺ channel blockers (nifedipine)
 - ▶ phosphodiesterase inhibitors (Cialis)
 - ▶ endothelin antagonists (bosentan)
 - ▶ prostacyclins (Flolan, Ventavis)
 - ▶ nitric oxide

FYI - Click to download article on medical advice for commercial air travelers
<http://www.aafp.org/afp/990901ap/801.html>

Decompression Sickness & Arterial Gas Embolism

Decompression sickness (DCS)

- ^ Rapidly decreased ambient pressure allows dissolved N₂ to leave solution and form enlarged bubbles in circulation.
 - ◆ Henry's law - N₂ leaves solution
 - ◆ Boyle's law - bubble enlargement

Decompression sickness (DCS)

^ Contexts:

- ◆ underwater diving - bends
- ◆ underground construction - caisson disease
- ◆ aircraft at altitude - loses cabin pressure - altitude DCS
- ◆ hyperbaric chambers

FYI - click for article on history of caisson disease
<http://archive.rubicon-foundation.org/dspace/bitstream/123456789/4028/1/15686275.pdf>

FYI - click for joke about mine workers
 Play mining joke

Decompression sickness (DCS)

^ Physical factors:

- ◆ depth (determines pressure)
- ◆ time at depth
- ◆ time for decompression
- ◆ altitude; e.g., mountain lakes, caves

Decompression sickness (DCS)

^ Pathophysiology - N₂ bubbles cause physical and biochemical damage to tissues:

- ◆ accumulate in joint capsules & muscles
- ◆ obstruct blood flow to spinal cord
- ◆ endothelial damage activates leukocytes and platelets ==>
 - inflammation
 - coagulopathy

Decompression sickness (DCS)

^ Predisposing factors:

- ◆ fatigue
- ◆ obesity
- ◆ dehydration
- ◆ hypothermia
- ◆ female gender

Decompression sickness (DCS)**^ Predisposing factors:**

- ◆ increased age
- ◆ history of DCS
- ◆ recent alcohol use
- ◆ flying within 24 H after diving (altitude DCS)
- ◆ cardiovascular shunt; e.g., PFO

Decompression sickness (DCS)**^ Manifestations**

- ◆ bends - pain in large joints
- ◆ chokes - cough, substernal pain
- ◆ skinny bends - cutaneous, itchy rash
- ◆ lymphedema

Decompression sickness (DCS)**^ Manifestations - spinal cord DCS**

- ◆ ascending paresthesia (tingling)
- ◆ ascending paralysis
- ◆ loss of bowel and bladder control

Arterial gas embolism (AGE)**^ Pathophysiology**

- ◆ rapid decompression
- ◆ alveolar gas expands and ruptures pulmonary vessels
- ◆ and/or passes through PFO; then,
- ◆ gas bubbles enter systemic circulation

Click for illustration of AGE

<http://www.scubish.com/dive-reference/3/images/fig3-11.JPG>

Arterial gas embolism (AGE)**^ Pathophysiology**

- ◆ blockage of arteries ==> distal ischemia
- ◆ bubbles cause cellular damage ==> leukocyte activation ==>
 - edema
 - coagulopathy ==> focal hemorrhages
 - increased permeability of blood-brain barrier

FYI - click for article on gas embolism

<http://anesthesia.ucsf.edu/neuroanesthesia/residents/respdf/VenousAirEmbolism.pdf>

Arterial gas embolism (AGE)**^ Manifestations (sudden onset)**

- ◆ bloody froth from mouth, nose
- ◆ marbling of skin
- ◆ headache
- ◆ confusion
- ◆ sensory deficits
- ◆ motor deficits
- ◆ convulsions (worst case)
- ◆ coma (worst case)
- ◆ death (worst case)

DCS & AGE prevention

- ▲ Pre-dive medical clearance
- ▲ Slow ascent - one-half the rate of smallest bubbles
- ▲ Breathing evenly during ascent - avoid breath holding
- ▲ No flying for 12 - 24 H after dives

FYI - click for article on scuba diving health information
<http://www.ccjm.org/content/73/8/711.full.pdf+html>

DCS & AGE management

- ▲ Basic life support
- ▲ Transport - low-flying craft
- ▲ Oxygen
- ▲ Recompression (hyperbaric chamber)
- ▲ Staged decompression

**Hyperbaric Oxygen
Therapy (HBOT)**

HBOT Definition

- ▲ The patient intermittently breathes 100% O₂ in a chamber pressurized to greater than 1.0 ATA

Actions (rationale)

- ▲ Increased ambient pressure
 - ◆ dissolves N₂ bubbles in tissues
 - ◆ shrinks gas bubbles
 - ◆ increases PO₂ in all tissues; e.g., at FIO₂ = 1.0 and 3 ATA, the PaO₂ = 2100 mm Hg ==> dissolved O₂ = 6.3 mL/dL

Effects

- ▲ Promotes genesis of new blood vessels (speeds wound healing)
- ▲ Kills some anaerobes
- ▲ Prevents growth of species; e.g., pseudomonas
- ▲ Prevents production of clostridial alpha toxin (gangrene)

Effects

- △ Increases bacteriocidal effectiveness of WBCs
- △ Reduces WBC adhesion in reperfusion injury, preventing release of proteases and free radicals

Indications

- △ Strong evidence - main treatment
 - ◆ decompression sickness
 - ◆ arterial gas embolism
 - ◆ severe CO poisoning

Indications

- △ Strong evidence as adjunctive treatment
 - ◆ prevention and treatment of radionecrosis
 - ◆ improved skin graft and flap healing
 - ◆ clostridial tissue infections

Indications

- △ Some evidence
 - ◆ refractory osteomyelitis
 - ◆ acute traumatic ischemic injury
 - ◆ prolonged failure of wound healing
 - ▶ diabetic ulcers
 - ▶ thermal burns
 - ▶ crush injury
 - ▶ skin grafts
 - ▶ sternal wound infections

Indications

- △ Some evidence
 - ◆ severe anemia
 - ◆ autism
 - ◆ cirrhosis
 - ◆ stroke
 - ◆ intracranial abscess
 - ◆ invasive fungal infections; e.g., aspergillus
 - ◆ cerebral palsy

Complications

- △ Fire hazard
- △ Claustrophobia
- △ Near-sightedness (reversible)
- △ Barotrauma - ear damage
- △ Oxygen toxicity - brain and lung
- △ Pulmonary edema
- △ DCS, AGE

FYI - Click for article on HBOT

<http://content.nejm.org/cgi/reprint/334/25/1642.pdf?ijkey=jUKDuJvHX0/2>

HBO chambers

- ▲ **Monoplace - one patient**
 - ◆ greater claustrophobia
 - ◆ portable
- ▲ **Multiplace - more than one patient**
 - ◆ chamber compressed with air - less fire hazard
 - ◆ O₂ administered via mask, ventilators

Click to see monoplace HBO chamber

<http://www.hyperbaric-oxygen-info.com/monoplace-hyperbaric-chambers.html>

Click for virtual tour of multiplace HBO chamber

http://www.hyperchamber.com/virtual_chamber_tour/

Procedures

- ▲ **Parameters:**
 - ◆ pressure - ATAs
 - ◆ duration of sessions
 - ◆ number of sessions
- ▲ **Parameters vary by condition treated**
 - ◆ AGE - up to 6 ATA
 - ◆ DCI - 2-4 H @ 2.5 - 3.0 ATA
 - ◆ Wound healing - 1.5 H @ 2-3 ATA for multiple treatments

Technical points

- ▲ O₂ toxicity decreased by intermittent changes to room air breathing
- ▲ Tube cuffs inflated with fluid
- ▲ IV infusion pumps lose accuracy in chambers
- ▲ Ventilator volume delivery is affected by pressure in chamber
- ▲ Sechrist 500A hyperbaric ventilator - for HBOT

Click for information on Sechrist 500A ventilator

<http://classes.kumc.edu/cahe/respcared/burn/ventilat.html>

Risk for personnel

- ▲ **Cerebral oxygen toxicity - seizures**
- ▲ **DCS**
- ▲ **Preventive measures:**
 - ◆ assessment for fitness to dive
 - ◆ adhering to decompression schedule
 - ◆ breathing O₂ during decompression
 - ◆ dividing chamber time among attendants
 - ◆ avoiding flying after HBO

Summary & Review

- ▲ **Gas laws**
 - ◆ Boyle's law - volume and pressure
 - ◆ Henry's law - pressure and dissolved gas contents
 - ◆ Dalton's law - pressure and partial pressure

Summary & Review

- ▲ **Physiologic responses - driven by hypobaric hypoxia - diminishing pressure with altitude**
 - ◆ hypoxic ventilatory response
 - ◆ HbO₂ curve shifts with hypocapnea and 2,3 DPG
 - ◆ acid-base balance - compensated respiratory alkalemia
 - ◆ pulmonary hypertension
 - ◆ erythropoietin - increased RBCs

Summary & Review

- ▲ High altitude illnesses
 - ◆ Acute mountain sickness
 - ◆ High altitude cerebral edema
 - ◆ High altitude pulmonary edema
 - ◆ Chronic mountain sickness

Summary & Review

- ▲ Decompression sickness
- ▲ Arterial gas embolism

Summary & Review

- ▲ Hyperbaric oxygen therapy
 - ◆ Actions - gas laws
 - ◆ Effects
 - ◆ Indications
 - ◆ Complications
 - ◆ Technical aspects - chambers, etc.
 - ◆ Risks to personnel

END**References**

- ▲ Mason NP. The physiology of high altitude: an introduction to the cardiorespiratory changes occurring on ascent to altitude. *Current Anaesthesia and Critical Care*, Volume 11, Issue 1, Pages 34-41.
<http://www.ericjlee.com/Mountains/The%20Physiology%20of%20High%20Altitude.pdf>
- ▲ Zubieta-Calleja GR, Paulev PE, Zubieta-Calleja L, Zubieta-Castillo G. Altitude adaptation through hematocrit changes. *J Physiol Pharmacol*. 2007 Nov;58 Suppl 5(Pt 2):811-8.
- ▲ Schoene RB. Illnesses at high altitude. *Chest*. 2008 Aug;134(2):402-16.
- ▲ Gallagher SA, Hackett PH. High-altitude illness. *Emerg Med Clin NA* 2004;22:329-355.
<http://www.altitudemedicine.org/publications/HighAltitudeIllness.pdf>

References

- ▲ Jafarian S, Gorouhi F, Ghergherechi M, Lotfi J. Respiratory rate within the first hour of ascent predicts subsequent acute mountain sickness severity. *Arch Iran Med*. 2008 Mar;11(2):152-6.
- ▲ Sartori C, et al. Salmeterol for the Prevention of High-Altitude Pulmonary Edema. *N Engl J Med* 2002 346: 1631-1636.
- ▲ Meier B, Lock JE. Contemporary Management of Patent Foramen Ovale. *Circulation* 2003;107: 5-9.
- ▲ Luks AM, Swenson ER. Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. *Chest*. 2008 Mar;133(3):744-55.
- ▲ Richalet JP, et al. Acetazolamide for Monge's disease: efficiency and tolerance of 6-month treatment. *Am J Respir Crit Care Med*. 2008 Jun 15;177(12):1370-6.

References

- ▲ Muhm JM, Rock PB, McMullin DL, Jones SP, Lu IL, Eilers KD, Space DR, McMullen A. Effect of aircraft-cabin altitude on passenger discomfort. *N Engl J Med.* 2007 Jul 5;357(1):18-27.
- ▲ Penalzoza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. *Circulation.* 2007 Mar ;115(9):1132-46.
- ▲ Grocott M, Montgomery H, Vercueil A. High-altitude physiology and pathophysiology: implications and relevance for intensive care medicine *Crit Care.* 2007;11(1):203.
- ▲ Bettles TN, McKenas DK. Medical advice for commercial air travelers. *Am Fam Physician.* 1999 Sep 1;60(3):801-8, 810.

References

- ▲ Allemann Y, Hutter D, Lipp E, Sartori C, Duplain H, Egli M, Cook S, Scherrer U, Seiler C. Patent foramen ovale and high-altitude pulmonary edema. *JAMA.* 2006 Dec 27;296(24):2954-8.
- ▲ Luks AM, Swenson ER. Travel to high altitude with pre-existing lung disease. *Eur Respir J.* 2007 Apr;29(4):770-92.
- ▲ Gertsch JH, et al. Randomised, double blind, placebo controlled comparison of ginkgo biloba and acetazolamide for prevention of acute mountain sickness among Himalayan trekkers: the prevention of high altitude illness trial. *BMJ.* 2004; 328: 797.
- ▲ Maggiorini M. High altitude-induced pulmonary oedema. *Cardiovasc Res.* 2006 Oct 1;72(1):41-50.

References

- ▲ Maggiorini M, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. *Ann Intern Med.* 2006 Oct 3;145(7):497-506.
- ▲ Leaf DE, Goldfarb DS. Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness. *J Appl Physiol.* 2007 Apr;102(4):1313-22.
- ▲ Aldashev AA, et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. *Thorax.* 2005 Aug;60(8):683-7.
- ▲ Neuman TS. Arterial gas embolism and decompression sickness. *News Physiol Sci.* 2002 Apr;17:77-81.

References

- ▲ Arias-Stella J, Kruger H, Recaverren S. Pathology of chronic mountain sickness. *Thorax* 1973;28:701-708.
- ▲ Zubieta-Castillo G, Zubieta-Castillo GR, Zubieta-Calleja L. Chronic mountain sickness: The reaction of physical disorders to chronic hypoxia. *J Phys & Pharm* 2006;57s:431-442.
- ▲ Leon-Velarde F, et al. Consensus statement on chronic and subacute high-altitude diseases. *High altitude med & biol* 2005;6:147-157.
- ▲ Neuman TS. Arterial gas embolism and decompression sickness. *News Physiol Sci.* 2002 Apr;17:77-81.

References

- ▲ Schwerzmann M, Seiler C. Recreational scuba diving, patent foramen ovale and their associated risks. *Swiss Med Wkly.* 2001 Jun 30;131(25-26):365-74.
- ▲ Torti SR, et al. Risk of decompression illness among 230 divers in relation to the presence and size of patent foramen ovale. *Eur Heart J.* 2004 Jun;25(12):1014-20.
- ▲ Tetzlaff K, Reuter M, Leplow B, Heller M, Bettinghausen E. Risk factors for pulmonary barotrauma in divers. *Chest.* 1997 Sep;112(3):654-9.
- ▲ Centers for Disease Control and Prevention (CDC). Carbon monoxide exposures after hurricane Ike - Texas, September 2008. *MMWR Morb Mortal Wkly Rep.* 2009 Aug 14;58(31):845-9.

References

- ▲ Gill AL, Bell CNA. Hyperbaric oxygen: its uses, mechanisms of action and outcomes. *QJM* 97: 385-395. Ong M. Hyperbaric oxygen therapy in the management of diabetic lower limb wounds. *Singapore Med J.* 2008 Feb;49(2):105-9.
- ▲ Weaver LK, Valentine KJ, Hopkins RO. Carbon monoxide poisoning: risk factors for cognitive sequelae and the role of hyperbaric oxygen. *Am J Respir Crit Care Med.* 2007 Sep 1;176(5):491-7. Epub 2007 May 11.
- ▲ Mills C, Bryson P. The role of hyperbaric oxygen therapy in the treatment of sternal wound infection. *Eur J Cardiothorac Surg.* 2006 Jul;30(1):153-9.

References

- ^Rossignol DA, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. *BMC Pediatr.* 2009 Mar 13;9:21.
- ^Wilkinson D, Doolette D. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. *Arch Surg.* 2004 Dec;139(12):1339-45.
- ^Weaver LK, et al. Hyperbaric oxygen for acute carbon monoxide poisoning. *N Engl J Med.* 2002 Oct 3;347(14):1057-67.
- ^Segal E, Menhusen MJ, Shawn S. Hyperbaric oxygen in the treatment of invasive fungal infections: a single-center experience. *Isr Med Assoc J.* 2007 May;9(5):355-7.

References

- ^Branger AB, Lambertsen CJ, Eckmann DM. Cerebral gas embolism absorption during hyperbaric therapy: theory. *J Appl Physiol.* 2001 Feb;90(2):593-600.
- ^Weaver LK, Howe S, Hopkins R, Chan KJ. Carboxyhemoglobin half-life in carbon monoxide-poisoned patients treated with 100% oxygen at atmospheric pressure. *Chest.* 2000 Mar;117(3):801-8.
- ^Turner M, Esaw M, Clark RJ. Carbon monoxide poisoning treated with hyperbaric oxygen: metabolic acidosis as a predictor of treatment requirements. *J Accid Emerg Med.* 1999 Mar;16(2):96-8.